Abo Bibliothek: Guest
Critical Reviews™ in Neurobiology

Erscheint 3 Ausgaben pro Jahr

ISSN Druckformat: 0892-0915

ISSN Online: 2375-0014

SJR: 0.121

Nootropics: Preclinical Results in the Light of Clinical Effects; Comparison with Tacrine

Volumen 10, Ausgabe 3-4, 1996, pp. 357-370
DOI: 10.1615/CritRevNeurobiol.v10.i3-4.40
Get accessGet access

ABSTRAKT

This review is meant to serve several purposes. First, it surveys the preclinical and clinical profiles of piracetam-like nootropics. Second, the conditions under which the nootropics are active in preclinical studies are identified and analyzed with a view to finding a common denominator that could explain the observed effects. Third, the clinical profile is examined, on the one hand to assess whether these drugs are in fact active in humans, and on the other to determine how the clinical effects of the nootropics compare with those of tacrine. Lastly, the clinical data are then further scrutinized to assess whether they fulfill the expectations based on the preclinical findings.

REFERENZIERT VON
  1. Thompson Simon B. N., Macdonald John, Coates Tony D., Improving Visual Memory with Aricept (Donepezil Hydrochloride, E2020) in Mild-to-Moderate Alzheimer's Disease, Clinical Gerontologist, 24, 1-2, 2001. Crossref

  2. Sandberg Anders, Cognition Enhancement, in Enhancing Human Capacities, 2014. Crossref

  3. Meck Warren H, Williams Christina L, Nootropic Drugs, in Encyclopedia of Cognitive Science, 2006. Crossref

  4. Yamada Kelvin A, Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease, Expert Opinion on Investigational Drugs, 9, 4, 2000. Crossref

  5. Bostrom Nick, Sandberg Anders, Cognitive Enhancement: Methods, Ethics, Regulatory Challenges, Science and Engineering Ethics, 15, 3, 2009. Crossref

  6. Flicker Leon, Grimley Evans John, Piracetam for dementia or cognitive impairment, Cochrane Database of Systematic Reviews, 2004. Crossref

  7. Yamada Kelvin A., Modulating Excitatory Synaptic Neurotransmission: Potential Treatment for Neurological Disease?, Neurobiology of Disease, 5, 2, 1998. Crossref

  8. Bair Byron D., FREQUENTLY MISSED DIAGNOSIS IN GERIATRIC PSYCHIATRY, Psychiatric Clinics of North America, 21, 4, 1998. Crossref

  9. Rosenzweig Mark R., Introduction to the Symposium on Drug Improvement of Memory, International Journal of Psychology, 33, 2, 1998. Crossref

  10. Albensi Benedict C., Igoechi Chiazor, Janigro Damir, Ilkanich Erin, Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?, American Journal of Alzheimer's Disease & Other Dementiasr, 19, 5, 2004. Crossref

  11. SANDBERG A., BOSTROM N., Converging Cognitive Enhancements, Annals of the New York Academy of Sciences, 1093, 1, 2006. Crossref

  12. Callahan Patrick M., Terry Alvin V., Peitsch Manuel C., Hoeng Julia, Koshibu Kyoko, Differential effects of alkaloids on memory in rodents, Scientific Reports, 11, 1, 2021. Crossref

  13. Gainetdinov Raul R., Mohn Amy R., Bohn Laura M., Caron Marc G., Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter, Proceedings of the National Academy of Sciences, 98, 20, 2001. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain